NAGE vs NBIX vs RARE vs FOLD vs SRPT

For growth investors, Niagen Bioscience Inc (NAGE) is the stronger pick with 29.

9% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Niagen Bioscience Inc (NAGE) offers the better valuation at 20. 9x trailing P/E (17. 3x forward), making it the more compelling value choice. Analysts rate Niagen Bioscience Inc (NAGE) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Niagen Bioscience Inc (NAGE) is the cheapest at 20.

9x versus Neurocrine Biosciences, Inc. at 32. 6x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Neurocrine Biosciences, Inc.

(NBIX) delivered a total return of +66. 9%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: NBIX returned +239. 2% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 61β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately 219% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Niagen Bioscience Inc (NAGE) carries a lower debt/equity ratio of 4% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Niagen Bioscience Inc (NAGE) is pulling ahead at 29.

9% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Niagen Bioscience Inc grew EPS 81. 8% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Neurocrine Biosciences, Inc.

(NBIX) is the more profitable company, earning 16. 7% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBIX leads at 21. 6% versus -79. 5% for RARE. At the gross margin level — before operating expenses — NBIX leads at 98. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 34. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NAGE: 139. 8% to $10. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), +119. 2% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +119. 2%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.